Prof. Philip N. Newsome

Director of the Centre for Liver Research & Professor of Experimental Hepatology, University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital, Birmingham

He graduated from the Medical School at the University of Edinburgh in 1995 and moved to Birmingham in 2007.

He runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. Professor Newsome has published over 75 research papers in scientific journals as well as many book chapters in the field of Non-Alcoholic Fatty Liver Disease (NAFLD). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapy in NAFLD published in the Lancet, and is also Chief Investigator on a study of Fibroscan in NAFLD. He is editor of a recently published textbook on Liver Transplantation, and chaired the national guidelines for liver transplantation in NAFLD. He sits on the NICE Guideline Development Group for NAFLD.

Prof. Philip N. Newsome
Centre for Liver Research & Professor of Experimental Hepatology
University of Birmingham

Contact: Loraine Brown

Tel: +44 7464 910 474


He has a large laboratory group focussing on the role of cell therapy in liver injury. He has received a range of funding including large project/programme grants (EUFP7, MRC and MRC/Wellcome Clinical Training Fellowships). As a Research Area Lead on the NIHR liver BRU (£13M; 2008-2017) he has established two cutting edge clinical trials which he is the Chief Investigator on. One of these, REALISTIC, is the largest clinical trial of haematopoietic stem cell therapy in patients with liver cirrhosis in Europe/US. He co-ordinates the MERLIN (EU FP7) consortium which includes a clinical trial of mesenchymal stromal cells in patients with primary sclerosing cholangitis. He has driven stem cell research at the University of Birmingham resulting in significant strategic investment in manufacturing facilities such as the Advanced Therapies Facility.

The success and significance of his work has led to many approaches from industry such that he has an extensive interaction with many bio-tech companies, ranging from provision of consultancy through to joint research projects.

This research portfolio has led to high impact publications throughout including both original articles (PNAS, Hepatology, Journal of Hepatology, Gut, American Journal of Transplantation, Annals of Internal Medicine, Lancet) and review articles (Gastroenterology, Journal of Hepatology).